Amylyx Pharmaceuticals (AMLX) Insider Trading & Ownership $3.36 +0.35 (+11.63%) Closing price 03/5/2025 04:00 PM EasternExtended Trading$3.36 0.00 (0.00%) As of 03/5/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Amylyx Pharmaceuticals (NASDAQ:AMLX) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage11.70%Number OfInsiders Buying(Last 12 Months)3Amount OfInsider Buying(Last 12 Months)$326,397.50Number OfInsiders Selling(Last 12 Months)4Amount OfInsider Selling(Last 12 Months)$213,028.98 Get AMLX Insider Trade Alerts Want to know when executives and insiders are buying or selling Amylyx Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address AMLX Insider Buying and Selling by Quarter Amylyx Pharmaceuticals Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails2/24/2025Gina MazzarielloInsiderSell4,169$3.15$13,132.35 2/3/2025Gina MazzarielloInsiderSell3,678$3.49$12,836.22 2/3/2025Joshua B CohenCEOSell11,851$3.47$41,122.97 1/6/2025Justin B KleeCEOSell7,471$4.04$30,182.84 9/30/2024Camille L BedrosianInsiderSell11,442$3.20$36,614.40 9/30/2024Justin B KleeCEOSell18,589$3.20$59,484.80 9/12/2024James M FratesCFOBuy40,000$2.53$101,200.00 9/3/2024George M Milne JrDirectorBuy100,000$2.20$220,000.00 5/15/2024Gina MazzarielloInsiderSell10,455$1.88$19,655.40 5/14/2024Daphne QuimiDirectorBuy2,750$1.89$5,197.50 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. (Data available from 1/1/2013 forward) AMLX Insider Trading Activity - Frequently Asked Questions Who is on Amylyx Pharmaceuticals's Insider Roster? The list of insiders at Amylyx Pharmaceuticals includes Camille L Bedrosian, Daphne Quimi, George M Milne Jr, Gina Mazzariello, Global Investors Lp Viking, James M Frates, Joshua B Cohen, Justin B Klee, Morningside Venture Investment, and Patrick D Yeramian. Learn more on insiders at AMLX. What percentage of Amylyx Pharmaceuticals stock is owned by insiders? 11.70% of Amylyx Pharmaceuticals stock is owned by insiders. Learn more on AMLX's insider holdings. Which Amylyx Pharmaceuticals insiders have been buying company stock? The following insiders have purchased AMLX shares in the last 24 months: Daphne Quimi ($5,197.50), George M Milne Jr ($220,000.00), and James M Frates ($101,200.00). How much insider buying is happening at Amylyx Pharmaceuticals? Insiders have purchased a total of 142,750 AMLX shares in the last 24 months for a total of $326,397.50 bought. Which Amylyx Pharmaceuticals insiders have been selling company stock? The following insiders have sold AMLX shares in the last 24 months: Camille L Bedrosian ($36,614.40), George M Milne Jr ($1,116,150.00), Gina Mazzariello ($127,709.05), James M Frates ($1,989,891.44), Joshua B Cohen ($118,571.52), Justin B Klee ($3,371,051.17), Morningside Venture Investment ($7,507,921.94), and Patrick D Yeramian ($3,648,369.06). How much insider selling is happening at Amylyx Pharmaceuticals? Insiders have sold a total of 638,796 Amylyx Pharmaceuticals shares in the last 24 months for a total of $17,916,278.58 sold. Amylyx Pharmaceuticals Key ExecutivesMr. Joshua B. Cohen (Age 32)Co-Founder, Co-CEO & Director Compensation: $1.08M1 recent tradesMr. Justin B. Klee (Age 33)Co-Founder, Co-CEO & Director Compensation: $1.08M2 recent tradesMr. James M. Frates M.B.A. (Age 57)Chief Financial Officer Compensation: $763.16k1 recent tradesMs. Gina M. Mazzariello (Age 53)Chief Legal Officer & General Counsel Compensation: $689.26k2 recent tradesDr. Camille L. Bedrosian M.D. (Age 71)Chief Medical Officer Compensation: $232.6k1 recent tradesMr. Tom HolmesChief Technical Operations OfficerLindsey AllenHead of Investor Relations & CommunicationsMs. Shauna HorvathHead of Global MarketingMs. Linda A. ArsenaultChief Human Resources OfficerMr. Chris AielloHead of Canada & GM More Insider Trading Tools from MarketBeat Related Companies PRTA Insider Ownership CDMO Insider Ownership AVDL Insider Ownership BCYC Insider Ownership IMNM Insider Ownership CRON Insider Ownership BCAX Insider Ownership AVXL Insider Ownership NUVB Insider Ownership RLAY Insider Ownership Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles 3 Stocks With Robust Growth Outlooks Insiders Are BuyingMETA Stock: Insider Selling Ramps Up—What It Means for InvestorsThese Are the Dividend Stocks Insiders Bought in JanuaryInsider Selling in Tech Stocks Spikes in Q43 Small-Cap Stocks Insiders and Institutions Are Buying This page (NASDAQ:AMLX) was last updated on 3/6/2025 by MarketBeat.com Staff From Our Partners77 Hedge Funds Are Betting On This Off-Radar MineralWith surging prices... supply shortages... and growing demand, hedge funds are betting big on potash. In fa...The Tomorrow Investor | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredAll Signs Point To Collapse - 401(k)s/IRAs /Are DoomedRetiring? Not so Fast..Hold Onto Your Bootstraps For A Long Road AheadAmerican Hartford Gold | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amylyx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amylyx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.